Strategic Partnerships Recent collaboration with Fred Hutchinson Cancer Center and Nature Biotechnology study highlights RBC’s capability to power high-impact, large-scale kinase profiling projects, signaling opportunities to engage with leading cancer research institutes and academic labs seeking comprehensive drug discovery services.

Global Footprint With US and EU facilities and a broad client base of over 2,000 since 20+ years, RBC offers scalable, geographically distributed operations that can support multinational pharma and biotech clients needing rapid turnaround, secure material handling, and cross-border workflows.

Robust Target Library An expansive library of over 2,000 validated drug targets and 1,000+ cell lines positions RBC as a one-stop shop for early discovery and target validation, appealing to companies seeking comprehensive, end-to-end protein production, screening, and in vivo capabilities.

Strong Leadership Growth Recent executive hires and ongoing leadership expansion (CFO, CBO, CCO, CPO) indicate a growth-focused roadmap and enhanced commercial, financial, and people operations, signaling readiness to scale partnerships with larger biotech portfolios and multi-year contracts.

Proven Track Record A history of serving diverse clients across 5,000+ projects annually and involvement in FDA-approved therapies demonstrates reliability and scientific rigor, making RBC a compelling vendor for risk-averse organizations prioritizing quality, speed, and regulatory-aligned drug discovery services.